FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.
The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of ...
The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients toward higher-priced insulin in order to reap ...
The Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx ...
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...
A new Idaho law that goes into effect in January reforms pharmacy benefit managers to increase transparency and cut ...
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...
The Federal Trade Commission sued on Friday the three largest pharmaceutical intermediaries charged with negotiating drug prices on behalf of insurers, claiming they are illegally maximizing profits ...
The Federal Trade Commission's administrative complaint follows an interim report from the agency regarding PBM practices.
In January, a new Idaho law will take effect requiring reform of business practices by pharmacy middlemen — in search of ...
OPINION - Patients rely on the quality care services provided by pharmacists and pharmacies. On behalf of pharmacies and the ...
PBMs have been under fire for years for alleged profiteering and anticompetitive conduct, but efforts to regulate the industry at the federal level have stalled in Congress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback